Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

471P - Risk factors associated with recurrence and survival in patients with locally advanced gastric cancer: Experience in a single center

Date

27 Jun 2024

Session

Poster Display session

Presenters

Sayako Miyagui Adame

Citation

Annals of Oncology (2024) 35 (suppl_1): S162-S204. 10.1016/annonc/annonc1482

Authors

S.M. Miyagui Adame1, M.D.C. Diaz Romero2, J. Cervantes Bojalil1, V. Salais Michaus1, G. Calderillo Ruiz1, M. Herrera1, E. Ruiz1, S. Zilli Hernández1, A.W. Saenz Mamani3, J. Melchor-Ruan1

Author affiliations

  • 1 INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico/MX
  • 2 INCAN - Instituto Nacional de Cancerologia, 14080 - Ciudad de Mexico/MX
  • 3 ISSSTE Hospita Regional de alta especialidad bicentenario de la Independencia, Tultitlán/MX

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 471P

Background

Gastric cancer is one of the neoplasms with higher incidence and mortality in the world and México. In patients with gastric cancer who underwent surgery, recurrence is the main cause of mortality. The present retrospective study aims to determine the clinicopathologic factors associated with recurrence and survival in patients with locally advanced gastric cancer (LAGC).

Methods

Clinicopathological data for patients who underwent curative resection for gastric cancer treated at the National Cancer Institute, between 2014 to 2023 were retrospectively analyzed. Pearson’s χ 2 test was used to compare differences between categorical variables. Statistical analysis was performed using SPSS V.26.

Results

We included 248 patients with LAGC who underwent curative resection, among them with median age of 56 (21 – 89) years and 52% males (n=129). Most patients underwent surgery initially (78.2%, n= 194) and had D2 lymphadenectomy (81.5%, n= 202); majority of lesions were found on the body (48.8%). Signet ring cells and grade 3 were detected in 50% (n= 124) and 76.2% (189) of tumors, respectively. According to the 8th edition American Joint Committee on Cancer (AJCC) staging system, most patients had stage III disease (55.6%, n= 138). Nearly half of all patients received adjuvant radiotherapy (57.3%, n=142) and most of patients received adjuvant chemotherapy (71.4%, n=177). Median disease-free survival was 29.29 months. 69% patients with LAGC had recurrence: 11.68% locoregional, 35.06% peritoneal and 53.2% distant non peritoneal recurrence. The factors associated with recurrence were chemotherapy regimen with cisplatin and fluorouracil (p=<0.001), stage III disease (p=< 0.001) and signet ring cells (p=0.015). Median global survival was 44.73 months and, in the same way, histology subtype, chemotherapy regimen and stage disease were the factors associated with mortality (cisplatin and fluorouracil, p=<0.001; stage III disease, p=< 0.001; and signet ring cells p=0.015). Adjuvant radiotherapy did not show a benefit in reducing recurrence nor survival.

Conclusions

In this study, we found that stage disease, chemotherapy regimen and signet ring cells were factors associated with recurrence and less survival.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.